» Articles » PMID: 15982768

Effect of Agmatine on Heteromeric N-methyl-D-aspartate Receptor Channels

Overview
Journal Neurosci Res
Publisher Elsevier
Specialty Neurology
Date 2005 Jun 29
PMID 15982768
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Endogenous polyamines like spermine are known to have four distinct effects on recombinant N-methyl-d-aspartate (NMDA) receptor channels: voltage-dependent inhibition, glycine-dependent stimulation, glycine-independent stimulation and decreased affinity to the agonist (l-glutamate). These effects are highly dependent on the constituting epsilon subunits (epsilon1-epsilon4) of the recombinant NMDA receptor channels. Agmatine reportedly inhibits native NMDA receptor channels in cultured hippocampal neurons. In the present investigation, the effects of agmatine on the epsilon/zeta heteromeric NMDA receptor channels expressed in Xenopus laevis oocytes were examined using the two-electrode voltage clamp method. Agmatine inhibited the four epsilon/zeta (epsilon1/zeta1, epsilon2/zeta1, epsilon3/zeta1 and epsilon4/zeta1) channels with similar sensitivity (an IC50 value of about 300microM at -70mV). This effect was dependent on the membrane potential and was more pronounced at hyperpolarized membrane potentials (voltage-dependent inhibition). Agmatine did not exhibit other stimulatory (glycine-dependent and -independent effects) or inhibitory (decreased affinity to l-glutamate) effects. These properties are similar to the pharmacological profile of well-characterized NMDA receptor channel blockers like phencyclidine and ketamine. Thus, regarding the effects on the NMDA receptor channels, agmatine is not like other endogenous polyamines rather it acts as a channel blocker.

Citing Articles

Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors.

Barua S, Kim J, Kim J, Kim J, Lee J Neurochem Res. 2019; 44(4):735-750.

PMID: 30610652 DOI: 10.1007/s11064-018-02712-1.


Putative agmatinase inhibitor for hypoxic-ischemic new born brain damage.

Piletz J, Klenotich S, Lee K, Zhu Q, Valente E, Collins M Neurotox Res. 2013; 24(2):176-90.

PMID: 23334804 PMC: 3692582. DOI: 10.1007/s12640-013-9376-5.


Agmatine : metabolic pathway and spectrum of activity in brain.

Halaris A, Plietz J CNS Drugs. 2007; 21(11):885-900.

PMID: 17927294 DOI: 10.2165/00023210-200721110-00002.


Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence.

Regunathan S AAPS J. 2006; 8(3):E479-84.

PMID: 17025265 PMC: 2761054. DOI: 10.1208/aapsj080356.